Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The bio-manufacturing sector has vast potential and is poised to drive a new wave of industrial revolution, leveraging industrial biotechnology to produce bio-based materials, chemicals, and bioenergy [3][4] - The global synthetic biology market is expected to maintain rapid growth, projected to approach $50 billion by 2028, with a compound annual growth rate (CAGR) of approximately 24% from 2023 to 2028 [22][24] - Technological breakthroughs and policy support are driving the synthetic biology industry forward, with significant advancements in gene synthesis, sequencing, and editing technologies [4][37] Summary by Sections Industry Overview - Bio-manufacturing utilizes industrial biotechnology, enzymes, and microbial cells, playing a crucial role in producing bio-based materials and chemicals [13] - Synthetic biology is a design-driven science that re-engineers biological systems for useful purposes, with applications across various sectors including healthcare, agriculture, and chemicals [13][22] Policy Support and Technological Breakthroughs - Governments worldwide are increasingly prioritizing synthetic biology, with strategic plans and funding initiatives to support its development [28][29] - The reduction in costs for gene synthesis and sequencing technologies has laid a solid foundation for the rapid advancement of synthetic biology [37] Synthetic Biology Reshaping Industry Models - Synthetic biology is transforming production models, offering more efficient and environmentally friendly synthesis solutions compared to traditional methods [4][22] - The industry is expected to significantly reduce carbon emissions, with estimates suggesting a reduction of 1 to 2.5 billion tons of CO2 annually by 2030 through industrial biotechnology [4] Related Companies - Companies to watch include Chuan Ning Bio, Kingfisher Biotech, and Kailai Ying, which are positioned to benefit from advancements in synthetic biology [5] Investment Recommendations - The report suggests focusing on companies like Chuan Ning Bio, Kingfisher Biotech, and others that are leveraging synthetic biology for growth [5]

Fundraising - A total of 81 new funds were registered this week, with a total scale of 53.504 billion RMB, the largest being the Beijing Economic and Technological Development Zone Government Investment Guidance Fund Phase II, which raised 10.00 billion RMB [3] - As of this week, the cumulative number of registered private equity funds is 631, with a total scale of 555.875 billion RMB [3] Investment - There were 57 investment events this week, with disclosed investment amounts totaling 3.886 billion RMB, the largest being an investment of over 500 million RMB in Shenzhen Ruidelin Biotechnology Co., Ltd. by Shenzhen Songhe Capital Management Co., Ltd. and others [5][6] - Shenzhen Ruidelin Biotechnology Co., Ltd. focuses on synthetic biology technology and aims to create innovative products and solutions in the field of synthetic biology [5] Mergers and Acquisitions - A total of 24 M&A events occurred this week, with disclosed transaction amounts reaching 11.803 billion RMB, the largest being an investment of 2.6 billion RMB by Fengxin New Era New Energy Materials Co., Ltd. and Jiangxi Feiyu New Energy Technology Co., Ltd. in Yichun Shengyuan Lithium Industry Co., Ltd. [12][13] - Yichun Shengyuan Lithium Industry Co., Ltd. is a mineral exploration and mining service provider, and the investment aims to enhance its business development [12] IPOs - Three companies went public this week, raising a total of 1.43 billion RMB, with the largest being Microbus International, which raised 80 million USD through an IPO on NASDAQ [16][17] - Microbus International provides a real-time bus operation information query platform, enhancing user convenience in ticket purchasing and verification [16]

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the ongoing active research in life sciences and the global wave of biotechnology revolution, which is accelerating integration into economic and social development, providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [3][4]. Summary by Sections 1.1 Secondary Market Performance - The synthetic biology sector saw an overall increase of 6.17% in stock performance during the week of February 24 to February 28, 2025, ranking first among sectors [14]. 1.2 Company Business Progress - Domestic companies are making significant advancements, such as: - Zhongyuan Biological's 350,000 tons/year green methanol project is progressing with the first phase expected to be completed in 24 months [22]. - Longi Green Energy and China Energy Construction Group signed a project for 300,000 tons/year green methanol, with a total investment of 6 billion yuan [22]. - Henghui Security's biodegradable polyester rubber project is on track to start production in Q4 2025 [23]. 1.3 Industry Financing Tracking - Financing activities in the synthetic biology sector are accelerating, with nearly a hundred companies completing new rounds of financing at the beginning of 2025. Notable examples include: - Nanjing Senqi New Materials Technology completed a multi-million yuan financing round, focusing on bio-based nanocellulose [28]. - Vivici, a precision fermentation dairy product company, raised €32.5 million in Series A funding to launch a new product [28]. 1.4 Company R&D Directions - Domestic research institutions are achieving breakthroughs in bio-based materials, such as: - The Ningbo Institute of Materials Technology and Engineering has made progress in synthesizing bio-based long-chain polyols [31]. - Wanhua Chemical launched a bio-based 1,3-butanediol product aimed at the cosmetics industry, emphasizing sustainability and low carbon emissions [31].

本周募资情况 本周新登记股权投资基金管理人共计0家，取消备案登记3家，全年截至目前累计股权投 资基金管理人数量为11家。本周新增备案基金数量为 81只 ，规模总计 535.04亿元 ，本周备案基金募资最多的为北京经济技术开发区政府投资引导基金二期（有限合 伙），募集100.00亿人民币。全年截至目前累计股权投资备案基金数量为631只，规模 总计5558.75亿元。（2025年2月21日-2025年2月27日） 新备案基金地域分布TOP5 涉及总金额693.36亿元人民币。 作者 | 私募通 来源 | 决策投资圈 （ID：PEDATAMAX） 清科创业（01945.HK）旗下私募通统计：截至本周五下午，募资、投资、上市和并购 共 165起 事件，涉及总金额 693.36亿 人民币。从交易金额来看，本周金额较大事件 是：2025年2月25日，奉新时代新能源材料有限公司、江西飞宇新能源科技有限公司对 宜春盛源锂业有限责任公司进行增资，出资金额是26.00亿人民币。从交易事件地域分 布看，目前主要分布在广东省、江苏省和北京市，占比为广东省19.1%，江苏省 14.3%，北京市13.1%。 01 02 本周投资情况 清 ...

Investment Rating - The report maintains an "A" rating for the new materials industry, indicating a positive outlook for the sector [1]. Core Insights - The chemical raw materials sector is currently experiencing a bottoming phase, with a slowdown in capacity expansion and a potential alleviation of intense competition and price wars. The overall profit margin for the industry is expected to remain between 3% and 5% in 2024, which is at a historical low. However, with the central economic work conference emphasizing the need to address "involution" competition, there is potential for improved industry order and profit recovery [1][34]. Summary by Sections 1. Market Performance and Valuation - The new materials index has shown significant volatility, underperforming the Shanghai Composite Index by 10.6% as of December 27, 2024. The index's performance was particularly weak in the first three quarters of 2024 but saw a recovery in the fourth quarter due to favorable policies [15][20]. 2. Focus Areas 2.1 Supply and Demand Dynamics - The vitamin sector is expected to maintain high prices for Vitamin E due to limited supply recovery from BASF's production facilities, which are aging and unable to meet demand. The report suggests monitoring companies like New Hope Liuhe and Zhejiang Medicine [42][59]. - The renewable energy materials sector is projected to benefit from a stable increase in wind power demand, with a significant rise in installed capacity and a self-regulatory agreement among wind turbine manufacturers to mitigate price competition. Companies like Times New Material and Mega Chip Color are highlighted for investment [44][60]. 2.2 Emerging Industry Opportunities - The bio-manufacturing sector is positioned for growth, particularly in synthetic biology and sustainable aviation fuel (SAF). The report emphasizes the importance of product selection and platform capabilities for companies in this space, recommending firms like Huaheng Biological and Meihua Biological [48][50]. - The special coatings market is expected to grow due to increasing military expenditures and the need for stealth materials. Companies such as Huaqin Technology and Jiachih Technology are noted for their potential in this area [52][61]. - The semiconductor materials sector is anticipated to benefit from the recovery of consumer electronics and AI applications, with a focus on domestic production capabilities. Companies like Stik and Aisen are recommended for investment [56][61]. - The humanoid robotics market is projected to drive demand for PEEK materials, with domestic companies expected to gain market share due to cost advantages. The report suggests monitoring firms like Zhongxin Fluorine Materials and Zhongyan Co. [58][61].

华康股份 2024 年度董事会工作报告 浙江华康药业股份有限公司 2024 年度董事会工作报告 2024 年，公司董事会严格按照《公司法》《公司章程》《上市公司治理准则》 《上海证券交易所股票上市规则》等法律法规以及公司制度的规定，恪尽职守， 切实履行股东大会赋予的各项职责，严格执行股东大会各项决议，勤勉尽责开展 各项工作；积极推进董事会各项决议实施，不断规范公司法人治理结构，保证董 事会科学决策和规范运作。现将公司董事会 2024 年度工作情况汇报如下： 一、2024 年度经营讨论分析 公司以"做世界领先的糖醇专家"为企业愿景，坚持执行"深耕主业、规模 倍增、卓越运营、管理变革"的战略目标和规划，持续筑牢主营业务根基，提升 核心竞争力，稳健发展主营业务。同时积极探索并开拓新产品领域，开拓新的增 长空间，为企业的长远发展注入源源不断的活力。 "200 万吨玉米精深加工健康食品配料项目"分两期建设，其中一期项目 1 华康股份 2024 年度董事会工作报告 "100 万吨玉米精深加工健康食品配料项目"于 2022 年 8 月启动，一期项目建 设期为 5 年，分两个阶段，第一阶段建设期 2 年，主要以液体糖浆类及部 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 华昊中天 港股｜挂牌上市 据IPO早知道消息，北京华昊中天生物医药股份有限公司（以下简称"华昊中天"）于2024年10月31 日正式以"2563"为股票代码在港交所主板挂牌上市。 华昊中天在本次IPO中发行1458.80万股H股，其中香港公开发售部分获21.45倍认购。同时，华昊 中天在本次IPO发行中引入了四名基石投资者，累计认购2300万美元——知名天使投资人龚虹嘉全 资拥有的富策认购1000万美元，润淼资产管理、TPG和百洋医药则分别认购800万美元、300万美元 和200万美元。 此前，华昊中天医药已获得包括龙磐投资、达晨财智、贝达药业、国投创业、倚锋资本、经纬创投、 建银国际、国药中金、天创资本、成都生物城等多家机构的投资。 成立于2002年的华昊中天医药作为一家合成生物学技术驱动的生物医药公司，致力于开发肿瘤创新 药，现已成功开发了专注于微生物代谢产物新药研发的三大核心技术平台。 截至2024年10月14日，华昊中天医药拥有一种已商业化产品以及19种其他管线候选产品，现有临床 试验及项 ...

据IPO早知道消息，北京华昊中天生物医药股份有限公司（以下简称"华昊中天"）于2024年10月31 日正式以"2563"为股票代码在港交所主板挂牌上市。 打破中国近二十年来缺乏自主研发的国产一类化疗创新药的局面。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 华昊中天在本次IPO中发行1458.80万股H股，其中香港公开发售部分获21.45倍认购。同时， 华昊 中天 在本次IPO发行中引入了四名基石投资者，累计认购2 300 万美元——知名天使投资人 龚虹嘉 全资拥有的富策 认购1 00 0万美元， 润淼资产管理 、T PG 和 百洋医药 则分别认购8 00 万美 元、3 00 万美元和2 00 万美元。 截至10:25，华昊中天报于每股24.6港元，较发行价上涨53.75%，市值89.69亿港元。 华昊中天董事长、执行董事、首席科学官兼首席营销官唐莉博士在上市致辞中表示："作为一家以合 成生物学技术驱动的生物医药公司，华昊中天致力于开发肿瘤创新药。此次成功上市，是华昊中天发 展过程中的重要里程碑，也是一个全新的开始。未来，我们将继续坚持研发和创新，推出更多创新药 产 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 美股｜挂牌上市 据IPO早知道消息，WeRide Inc.（以下简称"文远知行"）于北京时间2024年10月25日晚间正式 以"WRD"为股票代码在纳斯达克挂牌上市，成为"全球通用自动驾驶第一股"。 （Robotaxi）、自动驾驶小巴（Robobus）、自动驾驶货运车（Robovan）、自动驾驶环卫车 （Robosweeper）、高阶智能驾驶（Advanced Driving Solution）等五大产品矩阵，提供网约 车、随需公交、同城货运、智能环卫、高阶智能驾驶解决方案等多种服务。 根据灼识咨询的资料，文远知行是全球首家在7个国家30个城市进行产品运营和测试的自动驾驶公 司，同时也是全球唯一一家在四个国家（中国、阿联酋、新加坡、美国）获得自动驾驶车辆测试许可 的自动驾驶公司。 文远知行创始人兼CEO韩旭表示："7年的拼搏与坚守迎来了今日文远知行的整装再出发。非常感谢 投资人、客户、员工及各方合作伙伴对文远知行的信任和支持！在与各位的并肩同行下，我们共同创 造了今天这个重要的里程碑。成功上市对我们来说是一个新的起点，文远知行将继续坚持技术创新， ...

合成生物学技术驱动的生物医药公司。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，北京华昊中天生物医药股份有限公司（以下简称"华昊中天医药"）今起招股，至 28日结束，并计划于2024年10月31日正式以"2563"为股票代码在港交所主板挂牌上市。 财务数据方面。2022年和2023年，华昊中天医药的营收分别为3282万元和6663万元。今年前五个 月，华昊中天医药的营收从2023年同期的2704万元增加至2856万元。 华昊中天医药计划在本次IPO中发行1458.80万股H股，招股区间为每股16港元至22港元。 值得注意的是， 华昊中天 医药在本次IPO中引入了四名基石投资者，累计认购2 300 万美元——其 中，知名天使投资人 龚虹嘉全资拥有的富策 认购1 00 0万美元， 润淼资产管理 、T PG 和 百洋医 药 则分别认购8 00 万美元、3 00 万美元和2 00 万美元 。 此前，华昊中天医药已获得包括龙磐投资、达晨财智、贝达药业、国投创业、倚锋资本、经纬创投、 建银国际、国药中金、天创资本、成都生物城等多家机构的投资。 成立于2002 ...